Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma
NCT07891923
Summary
The goal of this clinical trial is to evaluate whether a modified (less frequent) dosing schedule of daratumumab, when added to standard VRd therapy, can be an effective induction regimen for treating newly diagnosed multiple myeloma (NDMM). The main questions it aims to answer are: 1. Does the modified (less frequent) daratumumab dosing regimen increase the rate of MRD (minimal residual disease) negativity after 4 cycles of induction therapy (as compared to standard VRd therapy)? 2. Is the modified less-frequent dosing schedule safe and does it achieve adequate drug levels 3. What is the clinical response of patients to the treatment? Treatment regimen Daratumumab (Dara), Bortezomib, Lenalidomide, and Dexamethasone will be given together for four cycles of induction therapy Duration of each cycle will be 28 days 1. Daratumumab will be given at standard dose of 16mg/kg - Day 1, 15, 29, 50, 71, and 92 (First three doses every 2 weeks, followed by the next three doses every 3 weeks). This will be given intravenously in saline 2. Bortezomib: 1.3 mg/m2 - Given once weekly subcutaneously (similar to insulin) 3. Lenalidomide: 15-25 mg orally for 21 days, followed by a 7-day gap. 4. Dexamethasone: 40mg given once weekly Response Assessment * Response assessment - A bone marrow test will be done within two weeks of end of cycle 4 in order to assess the cancer burden via a special test called MRD (minimal residual disease) in the bone marrow. * Blood tests will be performed to assess your response to treatment (serum protein electrophoresis, immunofixation electrophoresis and serum free light chain assay) after cycle 2 (between day 51-day 56) and cycle 4 (between 107-112). These blood tests are routinely done for all myeloma patients during their treatment to assess response.
Eligibility
Inclusion Criteria 1. Newly diagnosed multiple myeloma 2. ECOG performance status 0-2 3. Age ≥18 years of age 4. Acceptable liver functions, as specified below: Total bilirubin \<2 times upper limit of normal (ULN), Aspartate transaminase (AST; SGOT), alanine transaminase (ALT; SGPT) \<3 ULN 5. Acceptable hematological parameters: Hemoglobin \>7g/dl, Absolute neutrophil count (ANC) ≥500/mm3, platelet count ≥50,000/mm3 6. Creatinine clearance ≥30ml/minute (by Cockcroft-Gault formula) 7. Treatment naive or received ≤ 1 cycle (≤28 days) of bortezomib based triplet therapy Exclusion Criteria 1. Other plasma cell dyscrasias - Plasma cell leukemia (\>=5% circulating plasma cells in peripheral blood), AL Amyloidosis, POEMS syndrome 2. Patients with symptomatic central nervous system involvement (as per assessing clinician) 3. Patients with symptomatic obstructive airway disease, as per assessing clinician 4. New York Heart Association (NYHA) Class III or IV cardiac disease, or left ventricular ejection fraction \<40% 5. Human immunodeficiency virus (HIV) positive or HBsAg positive 6. Pregnant or breastfeeding female
Conditions2
Interventions4
Related trials
- A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients — Hangzhou Sumgen Biotech Co., Ltd.
- A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) — Merck Sharp & Dohme LLC
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma — University of Birmingham
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) — Nanjing IASO Biotechnology Co., Ltd.
- A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma — Qilu Pharmaceutical Co., Ltd.
- A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma — Hoffmann-La Roche
- A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma — Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned — Janssen Research & Development, LLC
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07891923